PubRank

Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases.

PubWeight™: 0.76‹?›

🔗 View Article (PMID 27926948)

Published in JAMA Oncol on December 07, 2016

Authors

Nolan Priedigkeit1, Ryan J Hartmaier2, Yijing Chen3, Damir Vareslija4, Ahmed Basudan5, Rebecca J Watters6, Roby Thomas7, Jose P Leone8, Peter C Lucas9, Rohit Bhargava9, Ronald L Hamilton10, Juliann Chmielecki2, Shannon L Puhalla11, Nancy E Davidson11, Steffi Oesterreich6, Adam M Brufsky11, Leonie Young4, Adrian V Lee12

Author Affiliations

1: Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania2Women's Cancer Research Center, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania3Magee-Women's Research Institute, Magee-Women's Research Hospital of University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania4Medical Scientist Training Program, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
2: Foundation Medicine, Cambridge, Massachusetts.
3: Women's Cancer Research Center, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania3Magee-Women's Research Institute, Magee-Women's Research Hospital of University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
4: Endocrine Oncology Research Group, Department of Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland.
5: Women's Cancer Research Center, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania3Magee-Women's Research Institute, Magee-Women's Research Hospital of University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania7Department of Human Genetics, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania.
6: Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania2Women's Cancer Research Center, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania3Magee-Women's Research Institute, Magee-Women's Research Hospital of University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
7: Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
8: Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City.
9: Women's Cancer Research Center, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania3Magee-Women's Research Institute, Magee-Women's Research Hospital of University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania10Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
10: Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
11: Women's Cancer Research Center, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania3Magee-Women's Research Institute, Magee-Women's Research Hospital of University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania8Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
12: Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania2Women's Cancer Research Center, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania3Magee-Women's Research Institute, Magee-Women's Research Hospital of University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania7Department of Human Genetics, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania.

Articles citing this ↘

Exome-capture RNA sequencing of decade-old breast cancers and matched decalcified bone metastases. JCI Insight (2017) 0.75

Articles cited by this ↗

The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res (2010) 97.51

Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol (2012) 5.43

Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov (2012) 4.72

Mechanisms of endocrine resistance in breast cancer. Annu Rev Med (2011) 4.32

Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol (2005) 3.18

Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol (2014) 2.75

Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol (2008) 2.12

Copynumber: Efficient algorithms for single- and multi-track copy number segmentation. BMC Genomics (2012) 1.74

Keratins in health and cancer: more than mere epithelial cell markers. Oncogene (2010) 1.61

Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov (2015) 1.51

DGIdb 2.0: mining clinically relevant drug-gene interactions. Nucleic Acids Res (2015) 1.41

Changes in keratin expression during metastatic progression of breast cancer: impact on the detection of circulating tumor cells. Clin Cancer Res (2012) 1.30

CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing. PLoS Comput Biol (2016) 0.95

Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain. Breast Cancer Res (2012) 0.95

Changing molecular profile of brain metastases compared with matched breast primary cancers and impact on clinical outcomes. Br J Cancer (2016) 0.80

Articles by these authors ⇆

Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes. Cancer Discov (2014) 0.96

High-Throughput Genomic Profiling of Adult Solid Tumors Reveals Novel Insights into Cancer Pathogenesis. Cancer Res (2017) 0.77

Genomic Profiling of a Large Set of Diverse Pediatric Cancers Identifies Known and Novel Mutations across Tumor Spectra. Cancer Res (2017) 0.75